Stocks · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Ascendis Pharma reported new data from its Phase 2 and Phase 3 trials showing that TransCon PTH provides sustained, clinically meaningful improvements in kidney function for adults with hypoparathyroidism.
Ascendis Pharma A/S (NASDAQ:ASND) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization
BioMarin Pharmaceutical announced it is discontinuing development of Voxzogo for Noonan syndrome due to study feasibility and treatment landscape concerns, though not due to safety or efficacy issues. Despite this setback, Voxzogo generated $472 million in first-half 2026 sales (up 9% YoY) and is on track to achieve blockbuster status with expected 2026 sales of $1.00-$1.05 billion. The drug faces increasing competition from Ascendis Pharma's Yuviwel and BridgeBio's infigratinib, though BioMarin secured a royalty-bearing settlement with Ascendis.
BioMarin Pharmaceutical Inc. announced it will hold a conference call and webcast to discuss its third quarter 2026 financial results on November 2, 2026.
Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and maintains $86 price target.
BioMarin Pharmaceutical is expected to report Q3 2026 earnings of $1.35 per share (up 1025% YoY) with revenues of $1.03 billion (up 32.7% YoY). The company has a positive Earnings ESP of +9.40% with a Zacks Rank #3 (Hold), suggesting it is likely to beat consensus estimates. BioMarin has beaten EPS estimates in 3 of the last 4 quarters, most recently delivering a +25% surprise.